Upadacitinib (Rinvoq)

CADTH recommends that Rinvoq should be reimbursed by public drug plans for the treatment of active psoriatic arthritis (PsA) if certain conditions are met. Rinvoq should only be reimbursed if it is prescribed by a rheumatologist or a clinician who has experience treating adult patients with active PsA and if it does not cost more than other biologic disease-modifying antirheumatic drugs (bDMARDs) or targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs). Rinvoq should only be covered to treat adult patients with active PsA who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs) in a similar way to other bDMARDs currently reimbursed by public drug plans.